Ai In Action

Today's guest is Melissa Landon, VP and Chief Strategist at Cyclica. Cyclica is a Toronto-Based globally recognized biotechnology company that leverages AI and computational biophysics to reshape the drug discovery process. Cyclica's proprietary structure-based and AI-augmented drug discovery platform includes Ligand Design for multi-targeted and multi-objective drug design, and Ligand Express for off-target profiling, systems biology linkages, and structural pharmacogenomic insights. Taken together, Ligand Design and Ligand Express design advanced lead-like molecules that minimize unwanted off-target effects, while providing a holistic understanding of a molecule's activity through integrated systems biology and structural pharmacogenomics. By doing more with Artificial Intelligence, Cyclica aims to revolutionize a system troubled with attrition and costly failures, accelerate the drug discovery process and develop medicines with greater precision. In the show, Melissa will tell you about: The fascinating wo